(Length of lecture - 38 minutes)

Daniel Petrylak, MD presents response rates and anti-tumor activity of checkpoint inhibition therapy in patients with advanced urothelial carcinoma and immunotherapy as initial therapy in cisplatin-ineligible patients and in patients with cisplatin pretreated disease.  Dr. Petrylak discusses trials that are on-going to explore immunotherapy based combinations and the use of immunotherapy in earlier stages of disease. 

Watch: Dr. Petryalk present: What is a checkpoint inhibitors and its mechanisms? What is a checkpoint inhibitors and its mechanisms?

Additional content on Immunotherapy of Advanced Bladder Cancer:

Watch - Immunotherapy in Bladder Cancer - Alan Bryce

Watch- Immunotherapy in Advanced Urothelial Cancer- Matthew Campbell

Immunotherapy of Advanced Bladder Cancer: The Next Frontier

EAU 2016 Immunotherapy for bladder cancer – benefits for all patients? - Session Highlights

Systemic Immunotherapy Bladder Cancer.. Get Ready! EVERYDAY UROLOGY- Full text article

Biography:
Daniel P Petrylak, MD. Professor of Medicine and Urology - Director, GU Translational Working Group, Co-Director, Signal Transduction Program Smilow Cancer Center, Yale University.